Patients, N | % | |
---|---|---|
Included into the study | 13,598 | 100 |
State | ||
SA | 3,526 | 25.9 |
Victoria | 10,072 | 74.1 |
Age groups | ||
< 55 | 2,059 | 15.1 |
56–65 | 4,851 | 35.7 |
65–75 | 4,711 | 34.6 |
> 75 | 1,977 | 14.5 |
Age (mean, SD) | 65.4 (9.6) | |
Residential area | ||
Metropolitan | 9,586 | 70.5 |
Regional/Rural | 3,250 | 23.9 |
Unknown | 762 | 5.6 |
SEIFA | ||
Lowest 10 % (0–20 %) | 1,751 | 12.9 |
Lowest 21–40 % | 2,245 | 16.5 |
Lowest 41–60 % | 2,075 | 15.3 |
Highest 61–80 % | 2,840 | 20.9 |
Highest 81–100 % | 4,334 | 31.9 |
Unknown | 353 | 2.6 |
Method of diagnosis | ||
TRUS | 11,518 | 84.7 |
TURP | 1,239 | 9.1 |
Other | 841 | 6.2 |
PSA (ng/mL) | ||
< 4 | 2,691 | 19.8 |
4.01–10 | 5,985 | 44.0 |
10.01–20 | 1,820 | 13.4 |
> 20.01 | 1,284 | 9.4 |
Unknown | 1,818 | 13.4 |
Grade Group | ||
Grade Group 1 (Gleason score ≤ 6) | 4,769 | 35.1 |
Grade Group 2 (Gleason score 3 + 4) | 3,771 | 27.7 |
Grade Group 3 (Gleason score 4 + 3) | 1,832 | 13.5 |
Grade Group 4 (Gleason score 8) | 1,264 | 9.3 |
Grade Group 5 (Gleason score >8) | 1,193 | 8.8 |
Unknown | 769 | 5.7 |
NCCN Risk | ||
Low | 3,352 | 24.7 |
Intermediate | 5,727 | 42.1 |
High | 2,943 | 21.6 |
Very high/Metastatic | 546 | 4.0 |
Unknown | 1,030 | 7.6 |